Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Shanghai Bio-heart Biological Technology Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.39 |
52 Week High | HK$4.58 |
52 Week Low | HK$1.31 |
Beta | -0.48 |
11 Month Change | -26.06% |
3 Month Change | -30.50% |
1 Year Change | -65.85% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -93.08% |
Recent News & Updates
Recent updates
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jul 24Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Feb 22Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Nov 03We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
May 12We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn
Sep 19Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jun 03Shareholder Returns
2185 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | 0.7% | 1.9% | 3.0% |
1Y | -65.8% | -44.3% | -0.6% |
Return vs Industry: 2185 underperformed the Hong Kong Medical Equipment industry which returned -45.4% over the past year.
Return vs Market: 2185 underperformed the Hong Kong Market which returned -1.6% over the past year.
Price Volatility
2185 volatility | |
---|---|
2185 Average Weekly Movement | 7.8% |
Medical Equipment Industry Average Movement | 6.7% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.5% |
10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2185's share price has been volatile over the past 3 months.
Volatility Over Time: 2185's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 32 | Philip Wang | www.bio-heart.com |
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People’s Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis.
Shanghai Bio-heart Biological Technology Co., Ltd. Fundamentals Summary
2185 fundamental statistics | |
---|---|
Market cap | HK$338.35m |
Earnings (TTM) | -HK$191.18m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs 2185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2185 income statement (TTM) | |
---|---|
Revenue | CN¥0 |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥0 |
Other Expenses | CN¥175.89m |
Earnings | -CN¥175.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 19, 2024
Earnings per share (EPS) | -0.72 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 2185 perform over the long term?
See historical performance and comparison